Cryoport's Partnership with Takeda's BioLife Plasma Services Aims to Change the World of Cellular Therapies for the Better

September 22, 2022

In early September 2022, Cryoport announced its strategic partnership with BioLife Plasma Services, whos parent company is the global biopharmaceutical company Takeda. Together, the two companies are...

Cryoport and Cell Matters Collaboration Aids in the Standardization of Cell Therapy Supply Chain Processes

July 01, 2022

The recent partnership between Cell Matters and Cryoport has proven to be extremely beneficial in addressing a critical step in cell and gene therapy research and commercialization, reducing risks...

RegMedNet Highlights Cryoport’s First Two Global Supply Chain Centers

June 30, 2022

Cryoport Systems' first two Global Supply Chain Centers in Morris Plains, New Jersey and Houston, Texas will provide critical support to major biotech companies around the world as well as play a...

Cryoport Expands Global Supply Chain Network through Recent Acquisition of Cell&Co BioServices

April 27, 2022

The recent acquisition of of Cell&Co BioServices by Cryoport, Inc. will help to expand global service offerings by generating opportunities for clinical trial and cell and gene therapy developers in...

New Global Supply Chain Center Launch Will Expand Cryoport's Presence in Houston Markets

April 23, 2022

Cryoport Systems' new Global Supply Chain Center, location in Houston, Texas, will service the massive life sciences research sector in the Houston metropolitan area and expand its local presence....

Strategic Partnership between Cryoport and Cell Matters will Greatly Improve Cryopreservation Services

February 02, 2022

To better deliver end-to-end cryopreservation services for leukapheresis derived therapies, Cryoport has strategically partnered with Cell Matters, S.A. In late January, Contract Pharma articulates...

Mergermarket: Cryoport Continues Opportunistic Acquisition Drive to Build Upon Current Markets

December 01, 2021

By Mintoi Chessa-Florea in London – editor of Mergermarket, an Acuris companyOriginally published by Mergermarket and re-published with author permission

The Future of Life Sciences Supply Chain Industry: 4G/5G Network Technology Adoption

October 08, 2021

Logistics & Transportation Review features Cryoport Systems' Chief Operating Officer, Phil Wilson, on a critical and transparent conversation of technology changes coming up on active shipment...

In Light Of The Pandemic, Here Are The 5 Things We Need To Do To Improve The US Healthcare System - Authority Magazine

August 17, 2021

Authority Magazine interviews Mark Sawicki, CEO of Cryoport Systems, on his expertise in the science, pharmaceutical and healthcare industry. Sawicki takes on his perspective of the current state of...

Cryoport Recognized as the King of Cool in Temperature-Controlled Logistics

April 21, 2021

With the growing market of cell and gene therapy manufacturing, Cryoport's scalability in providing storage and logistics capabilities for these life-saving therapies are now more important than ever.

Reshaping The Pharmaceutical Supply Chain - Contract Pharma Q&A

March 04, 2021

While the COVID-19 vaccine rollouts are excellent news, they will impact the pharma and biopharma supply chain. Cryoport Systems CEO Mark Sawicki outlines what to expect the rest of the year in a new

2021 Predictions for Regenerative Medicine as the Pandemic Continues

January 29, 2021

While the pandemic continues to disrupt many industries, including regenerative medicineit’s not all bad news -- in fact, there are likely some bright spots ahead for the industry this year. 

In an

Bloomberg Interview: Cryoport, Inc. CEO Discusses Vaccine Distribution Complexities

December 03, 2020

Jerrell Shelton, Chief Executive Officer of Cryoport, Inc. recently participated in a live interview on Bloomberg, discussing the complexities and challenges of logistic vaccine distribution, as well...

Bringing New Efficiencies to the Animal Health Sector

December 02, 2020

By Joseph Harvey – editor of IHS Markit Animal Health (formerly Animal Pharm)Originally published by IHS Markit Animal Health and re-published with author permission

Building A Patient-Centric Supply Chain for Cell and Gene Therapies

October 14, 2020

Mark Sawicki, Chief Executive Officer of Cryoport Systems, in collaboration with our strategic partners, Lonza and Vineti,  published a new white paper featured in the peer-reviewed journal ...

ISO 21973: Standardizing Best Practices for Transporting Cell and Gene Therapies

September 30, 2020

The much-anticipated ISO 21973:2020 has arrived, supplying a set of guidelines and best practices for the transportation of cell and gene therapies. Cryoport’s experts played a role in developing...

Navigating the New Normal in the Transportation Industry as the Pandemic Continues

July 17, 2020

 

The last few months have been unprecedented in world history. The pandemic that is gripping the world has spared no country, culture or corner, and it has highlighted the gaps in many companies’...

Contract Pharma Features Cryoport Growth and Innovation

June 23, 2020

A new Contract Pharma article is all about Cryoport!

Life Sciences in 2020: Biospace Interviews Mark Sawicki on Impending Developments in Cell and Gene Therapy

January 03, 2020

Commercial Officer Mark Sawicki brings more than a sales background to the company: He also holds a Ph.D. in biochemistry and has a distinguished career in global biopharmaceutical development.  

...

The Future is Now: CCO Mark Sawicki Shares the Effects of New Technology on Cold Chain Logistics in Pharma Manufacturing

December 04, 2019

A new article for Pharma Manufacturing breaks down the technology innovations that are changing cold chain logistics.

Cryoport-Lonza Partnership Featured in Contract Pharma and Biopharma Dive

November 12, 2019

Cryoport is expanding its impact on regenerative medicine development and distribution via a new partnership with Lonza 

New Cryoport Partnerships Featured in Biopharma-Reporter, Contract Pharma, and PharmaExec.com

October 15, 2019

“The past year has seen Cryoport establish multiple collaborations and expansions of its offering,” says a new article in BioPharma-Reporter, “due to the booming cell and gene therapy space and the...

As More Cell and Gene Therapies Go to Market, Manufacturing Challenges Abound: Cryoport’s Ryan Carpentier Predicts Important Industry Trends in Contract Pharma

September 24, 2019

With just a handful of cell and gene therapies currently on the market, we’ve only seen the tip of the iceberg. 

That’s how Cryoport’s Executive Director of Business Development, Ryan Carpentier,...

Ryan Carpentier Discusses CAR T Therapy Successes and Challenges in Contract Pharma

September 10, 2019

In a new article for Contract Pharma, Cryoport Executive Director of Business Development Ryan Carpentier explains the exciting new opportunities of CAR T-cell immunotherapy, which enables a...

New Cryoport-Vineti Partnership Provides Expanded Supply Chain Services for Cell and Gene Therapy Developers: Outsourcing Pharma, Pharmaceutical Commerce Publications

September 10, 2019

New articles in Outsourcing Pharma and Pharmaceutical Commerce highlight the exciting benefits of the recently announced partnership between Cryoport and Vineti

Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC